{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:17:50Z","timestamp":1791011870998,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,7,19]],"date-time":"2005-07-19T00:00:00Z","timestamp":1121731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> It would be useful to predict the future development of hyperparathyroidism before treatment with active vitamin D agents. Fibroblast growth factor 23 (FGF23) is a newly identified humoral phosphaturic factor. Positive correlation was found between parathyroid function and serum FGF23 levels in dialysis patients. Interestingly, FGF23 levels showed even better correlation with intact parathyroid hormone (iPTH) levels 2\u2003years after the sample collection for the FGF23 measurement. In long\u2010term dialysis patients with mild secondary hyperparathyroidism, serum FGF23 level was the best screening test to discriminate patients with future advanced secondary hyperparathyroidism within 2\u2003years. In dialysis patients with advanced secondary hyperparathyroidism, the pretreatment FGF23 levels, as well as iPTH levels, significantly affected the outcome of calcitriol therapy. Thus, the measurement of serum FGF23 level is a promising laboratory examination to predict the future development of secondary hyperparathyroidism. The mechanism of this phenomenon, however, remains to be revealed.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2005.00291.x","type":"journal-article","created":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T01:26:10Z","timestamp":1121822770000},"page":"328-330","source":"Crossref","is-referenced-by-count":15,"title":["Role of Circulating Fibroblast Growth Factor 23 in the Development of Secondary Hyperparathyroidism"],"prefix":"10.1111","volume":"9","author":[{"given":"Junichiro J","family":"Kazama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitake","family":"Gejyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,7,19]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116720"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90352-8"},{"issue":"1","key":"e_1_2_5_4_2","first-page":"iii31","article-title":"Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients","volume":"18","author":"Fukagawa M","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"e_1_2_5_5_2","first-page":"iii34","article-title":"Evaluation of blood supply to the parathyroid glands in secondary hyperparathyroidism compared with histopathology","volume":"18","author":"Onoda N","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.3696"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00016.2003"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00604.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","unstructured":"NakanishiS KazamaJJ Nii\u2010KonoTet al.Serum fibroblast growth factor\u201023 levels predict the future refractory hyperparathyroidism in dialysis patients.Kidney Int2005;67:1171\u20138.","DOI":"10.1111\/j.1523-1755.2005.00184.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","unstructured":"KazamaJJ SatoF OmoriKet al.Pretreatment serum FGF\u201023 levels predict the efficacy of calcitriol therapy in dialysis patients.Kidney Int2005;67:1120\u20135.","DOI":"10.1111\/j.1523-1755.2005.00178.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.04.029"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00328.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M408903200"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(04)00817-0"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2004.06.014"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510055"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2005.00291.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2005.00291.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T20:30:38Z","timestamp":1697056238000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2005.00291.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,19]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1744-9987.2005.00291.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2005.00291.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,19]]}}}